The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Using Immunotherapy for the Treatment of mCRC

Thierry Andre, MD
Published Online:7:18 PM, Mon March 12, 2018

Thierry Andre, MD, a professor of medical oncology at the University Pierre et Marie Curie, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses factors that a community oncologist should consider when choosing the right treatment for patients with metastatic colorectal cancer.

To date, the best way to treat patients with colorectal or metastatic colorectal cancer is with radiation. This is the standard of care for all gastric cancers at the St. Antoine Hospital in Paris, Andre explains.

Despite the success in the field of immunotherapies, every patient needs to be looked at individually before coming up with a treatment regimen. Immunotherapies should only be used on patients that can expect to benefit from this treatment. 

With combination therapies, it is better to treat a bigger population, Andre says. Rather than using this treatment only for patients considered microsatellite instability-high colorectal cancer, combination therapies can be used on a much broader range of patients.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.